TechnoPhage
↗Lisbon, Portugal
TechnoPhage is an innovative Portuguese biopharmaceutical company founded in 2005 and headquartered in Lisbon. The company is committed to the research and development of new biological molecules using bacteriophage technology and antibody fragments, targeting therapeutic areas including infection (particularly antimicrobial-resistant infections), neuroscience, and ophthalmology. TechnoPhage specializes in the development of bacteriophage cocktails (phage therapy) as novel treatments for serious bacterial infections resistant to conventional antibiotics. The company has in-house capabilities for process development, formulation, and Good Manufacturing Practice (GMP) production, with a newly launched GMP manufacturing facility at Venda Nova, Amadora, Portugal. TechnoPhage operates within the growing Portuguese biotech ecosystem and serves as a co-promoter of the Bio-Hub initiative, a national platform for biopharmaceutical development, production, and commercialization.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology | Biopharmaceuticals
Sub-Industry:Phage Therapy | Bacteriophage therapeutics | Antibody fragments
SIZE & FINANCIALS
Employees:11-50
Revenue:$3M (2024-2025 estimate based on early-stage clinical company)
Founded:2005
Ownership:private
Status:operating
FUNDING
Stage:Late Stage Biotech/Pre-Commercial
Total Raised:$45.8K (documented grant only; actual funding likely significantly higher but not publicly disclosed)
Investors:Johnson & Johnson Innovation - JLABS, European Commission, UTEN Portugal, Portuguese Government (PRR Grant - €19M for Bio-Hub project)
PIPELINE
Stage:Phase 1/IIa through Phase 3 in development
Lead Drug Stage:Phase 2b (REVERSE 2 ongoing for TP-102)
Modalities:Bacteriophage cocktails, Monoclonal antibodies, Antibody fragments, Phage-based biologics
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:VectorB2B – Drug Developing (Association for Biotechnology Research, founded 2019, co-promoted by TechnoPhage and University of Lisbon), LX Bio – Pharmaceuticals, S.A. (founded 2021, focused on late-phase clinical trials, production, and commercialization)
Key Partnerships:PHAXIAM Therapeutics (January 2025 strategic collaboration on Individualized GMP Phages Therapies against antimicrobial-resistant infections; goal of 25 GMP phages by end 2025, 35-45 by end 2026), University of Lisbon, Faculty of Pharmacy (Bio-Hub consortium partner), Portuguese Government (PRR Grant program for Bio-Hub initiative - €19M incentive of €35M total investment), Johnson & Johnson JLABS (investor and strategic partner)
COMPETITION
Position:Niche Player / Emerging (leader in European phage therapy; significant competitive advantage through GMP manufacturing expertise and partnerships)
Competitors:PHAXIAM Therapeutics, Locus Biosciences, Armata Pharmaceuticals, BiomX Inc., Adaptive Phage Therapeutics, Phico Therapeutics, SNIPR Biome, Eligo Bioscience +7 more
LEADERSHIP
Key Executives:
Miguel Garcia - Co-founder and CEO
Sofia Côrte-Real - Chief Scientific Officer (CSO) and Deputy CEO
Margarida Barreto - Clinical Trials Director
Carla Oliveira - Financial Director
Kátia Frota - Human Resources Manager
Francisco - Co-CEO of VectorB2B, Head of Industrial/Commercial Units
Scientific Founders:Miguel Garcia (PhD Pharmacy, co-founder)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TechnoPhage. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.